BR112022011445A2 - Composição imunoestimuladora e uso da mesma - Google Patents
Composição imunoestimuladora e uso da mesmaInfo
- Publication number
- BR112022011445A2 BR112022011445A2 BR112022011445A BR112022011445A BR112022011445A2 BR 112022011445 A2 BR112022011445 A2 BR 112022011445A2 BR 112022011445 A BR112022011445 A BR 112022011445A BR 112022011445 A BR112022011445 A BR 112022011445A BR 112022011445 A2 BR112022011445 A2 BR 112022011445A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunostimulatory composition
- motif
- cpg
- saponin
- immunostimulatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
COMPOSIÇÃO IMUNOESTIMULADORA E USO DA MESMA. A presente invenção refere-se a uma composição imunoestimuladora, compreendendo uma saponina e oligodesoxinucleotídeos CpG, ou composta de um adjuvante contendo saponina e oligodesoxinucleotídeos CpG, em que a sequência do oligodesoxinucleotídeo CpG tem duas ou mais cópias do motivo 5'-TTCGTT-3' ou motivo 5'-TCGTCGTCG-3'. Também é fornecido o uso da composição imunoestimuladora na preparação de um fármaco para o tratamento de doenças.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911279536 | 2019-12-13 | ||
PCT/CN2020/135572 WO2021115410A1 (zh) | 2019-12-13 | 2020-12-11 | 免疫刺激组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022011445A2 true BR112022011445A2 (pt) | 2022-08-30 |
Family
ID=76329610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011445A BR112022011445A2 (pt) | 2019-12-13 | 2020-12-11 | Composição imunoestimuladora e uso da mesma |
Country Status (11)
Country | Link |
---|---|
US (3) | US20230076371A1 (pt) |
EP (3) | EP4074336A1 (pt) |
JP (3) | JP2023506440A (pt) |
KR (2) | KR20220114032A (pt) |
CN (3) | CN112972670B (pt) |
AU (2) | AU2020400234A1 (pt) |
BR (1) | BR112022011445A2 (pt) |
CA (2) | CA3161638A1 (pt) |
TW (3) | TW202128217A (pt) |
WO (3) | WO2021115409A1 (pt) |
ZA (1) | ZA202207790B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023506440A (ja) * | 2019-12-13 | 2023-02-16 | 遠大賽威信生命科学(南京)有限公司 | 免疫刺激性組成物及びその用途 |
CN116327912A (zh) * | 2021-12-23 | 2023-06-27 | 上海泽润生物科技有限公司 | 带状疱疹疫苗组合物 |
CN114891072B (zh) * | 2022-03-11 | 2023-07-04 | 上海博唯生物科技有限公司 | 预防和/或治疗疱疹病毒的截短的疫苗抗原肽及其制备方法和应用 |
CN117653724A (zh) * | 2022-09-07 | 2024-03-08 | 远大赛威信生命科学(南京)有限公司 | 一种用于预防乙型肝炎病毒感染的药物组合物及其应用 |
CN116159134A (zh) * | 2023-01-31 | 2023-05-26 | 四川大学 | 七叶皂苷和/或其盐化合物作为佐剂在疫苗中的应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE315405T1 (de) * | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
CZ303515B6 (cs) * | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvantní prostredek |
TR200503031T2 (tr) * | 1999-09-25 | 2005-09-21 | University Of Iowa Research Foundation | İmmünostimülatör nükleik asitler |
CA2397374A1 (en) | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB0419846D0 (en) * | 2004-09-07 | 2004-10-13 | Chiron Srl | Vaccine adjuvants for saccharides |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AU2007342345B9 (en) * | 2006-12-28 | 2013-09-12 | The Trustees Of The University Of Pennsylvania | Herpes Simplex Virus combined subunit vaccines and methods of use thereof |
CN101979566B (zh) * | 2008-01-23 | 2013-05-01 | 许洪林 | 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用 |
CN101559225B (zh) * | 2008-04-18 | 2012-07-11 | 北京生物制品研究所 | 脑膜炎球菌疫苗 |
CN101675994B (zh) * | 2008-09-19 | 2012-07-25 | 齐鲁制药有限公司 | 治疗性疫苗制剂 |
PL2376107T3 (pl) * | 2008-12-09 | 2014-09-30 | Coley Pharm Group Inc | Oligonukleotydy immunostymulujące |
US20120121630A1 (en) * | 2009-07-24 | 2012-05-17 | Bryan Janine T | Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast |
KR20140007404A (ko) * | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법 |
CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
BE1022523B1 (fr) * | 2014-12-18 | 2016-05-20 | Glaxosmithkline Biologicals Sa | Vaccination |
CN107249629A (zh) * | 2015-02-26 | 2017-10-13 | 生控基因疫苗股份有限公司 | 包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物 |
CN104873969B (zh) * | 2015-04-16 | 2018-06-19 | 南京赛威信生物医药有限公司 | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 |
CA3002508A1 (en) * | 2016-01-12 | 2017-07-20 | Ulrike Protzer | Means and methods for treating hbv |
CN105906721B (zh) * | 2016-06-21 | 2020-02-28 | 芜湖天明生物技术有限公司 | 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法 |
EP3545972A4 (en) * | 2016-11-25 | 2020-05-13 | Mogam Institute For Biomedical Research | VARICELLA AND ZONA VIRUS VACCINE |
AU2017389221B2 (en) * | 2016-12-26 | 2020-10-08 | Access To Advanced Health Institute | Herpes zoster vaccine composition |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
CN108330145B (zh) | 2017-12-11 | 2021-06-11 | 远大赛威信生命科学(南京)有限公司 | 重组乙肝表面抗原的生产方法 |
CN108047316B (zh) | 2018-01-04 | 2021-06-15 | 远大赛威信生命科学(南京)有限公司 | 重组乙肝核心抗原的分离纯化方法 |
WO2020134682A1 (zh) * | 2018-12-24 | 2020-07-02 | 南京远大赛威信生物医药有限公司 | 用于治疗乙型肝炎的药物制剂及其制备方法和用途 |
JP2023506440A (ja) * | 2019-12-13 | 2023-02-16 | 遠大賽威信生命科学(南京)有限公司 | 免疫刺激性組成物及びその用途 |
-
2020
- 2020-12-11 JP JP2022535201A patent/JP2023506440A/ja active Pending
- 2020-12-11 JP JP2022535199A patent/JP2023506439A/ja active Pending
- 2020-12-11 EP EP20900086.8A patent/EP4074336A1/en active Pending
- 2020-12-11 TW TW109143764A patent/TW202128217A/zh unknown
- 2020-12-11 WO PCT/CN2020/135571 patent/WO2021115409A1/zh unknown
- 2020-12-11 US US17/784,086 patent/US20230076371A1/en active Pending
- 2020-12-11 CN CN202011456366.1A patent/CN112972670B/zh active Active
- 2020-12-11 CA CA3161638A patent/CA3161638A1/en active Pending
- 2020-12-11 KR KR1020227023841A patent/KR20220114032A/ko unknown
- 2020-12-11 WO PCT/CN2020/135570 patent/WO2021115408A1/zh unknown
- 2020-12-11 EP EP20897828.8A patent/EP4074334A1/en active Pending
- 2020-12-11 TW TW109143765A patent/TW202128219A/zh unknown
- 2020-12-11 JP JP2022535203A patent/JP2023506441A/ja active Pending
- 2020-12-11 US US17/784,089 patent/US20230040021A1/en active Pending
- 2020-12-11 AU AU2020400234A patent/AU2020400234A1/en active Pending
- 2020-12-11 TW TW109143766A patent/TW202128216A/zh unknown
- 2020-12-11 CN CN202011456435.9A patent/CN112972671B/zh active Active
- 2020-12-11 CN CN202011459500.3A patent/CN112972672B/zh active Active
- 2020-12-11 EP EP20897830.4A patent/EP4074335A1/en active Pending
- 2020-12-11 BR BR112022011445A patent/BR112022011445A2/pt unknown
- 2020-12-11 KR KR1020227023837A patent/KR20220114031A/ko unknown
- 2020-12-11 AU AU2020403296A patent/AU2020403296A1/en active Pending
- 2020-12-11 WO PCT/CN2020/135572 patent/WO2021115410A1/zh active Application Filing
- 2020-12-11 CA CA3161628A patent/CA3161628A1/en active Pending
- 2020-12-11 US US17/784,081 patent/US20230073321A1/en active Pending
-
2022
- 2022-07-13 ZA ZA2022/07790A patent/ZA202207790B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202128216A (zh) | 2021-08-01 |
JP2023506441A (ja) | 2023-02-16 |
KR20220114031A (ko) | 2022-08-17 |
US20230073321A1 (en) | 2023-03-09 |
TW202128217A (zh) | 2021-08-01 |
CN112972671B (zh) | 2024-04-19 |
JP2023506440A (ja) | 2023-02-16 |
WO2021115409A1 (zh) | 2021-06-17 |
TW202128219A (zh) | 2021-08-01 |
AU2020400234A1 (en) | 2022-07-07 |
US20230040021A1 (en) | 2023-02-09 |
KR20220114032A (ko) | 2022-08-17 |
CN112972672B (zh) | 2024-04-19 |
CN112972671A (zh) | 2021-06-18 |
US20230076371A1 (en) | 2023-03-09 |
AU2020403296A1 (en) | 2022-07-07 |
ZA202207790B (en) | 2023-10-25 |
EP4074334A1 (en) | 2022-10-19 |
CA3161638A1 (en) | 2021-06-17 |
CA3161628A1 (en) | 2021-06-17 |
CN112972670A (zh) | 2021-06-18 |
EP4074335A1 (en) | 2022-10-19 |
CN112972672A (zh) | 2021-06-18 |
CN112972670B (zh) | 2023-12-19 |
JP2023506439A (ja) | 2023-02-16 |
EP4074336A1 (en) | 2022-10-19 |
WO2021115410A1 (zh) | 2021-06-17 |
WO2021115408A1 (zh) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022011445A2 (pt) | Composição imunoestimuladora e uso da mesma | |
BR112019000598A2 (pt) | rna para terapia de câncer | |
BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
GT200500137A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis. | |
BRPI0416205A (pt) | uso de antibióticos como adjuvantes de vacina | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
BRPI0611550A2 (pt) | uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto | |
CL2020000879A1 (es) | Análogos de saponina de triterpeno. | |
CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
BR112019022307A2 (pt) | Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. | |
ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
BR102018071551A2 (pt) | compostos, uso de compostos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo 7,11b-dihydro-6h-indeno[2,1-c]chromene-3,6a,9,10-tetrol, seus derivados ou análogos, neutros ou ionizados, para prevenção e/ou terapia senolítica | |
BRPI0406673A (pt) | Método para o tratamento ou profilaxia e composição para uso no tratamento ou profilaxia de um ou mais sintomas de uma infecção por herpes viral em um indivìduo, e, uso de uma composição compreendendo um sal citrato e/ou um succinato | |
BRPI0511864A (pt) | uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento | |
BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
BRPI0414442A (pt) | composições de vacina de dna e métodos de utilização |